Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29175759 | 0.99 | KMT2A (0.59) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL8301782 | 0.99 | KMT2A (0.59) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL27413443 | 0.97 | KMT2A (0.54) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL1804937 | 0.94 | PIN1 (0.56) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL384450 | 0.89 | PIN1 (0.51) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL1265079 | 0.88 | GSK3A (0.57) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL1265078 | 0.88 | GSK3A (0.57) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL14589028 | 0.88 | GSK3A (0.57) | KMT2ACDK2PIN1AXLMEN1 | |
| SCHEMBL15974075 | 0.86 | PIN1 (0.46) | KMT2ACDK2PIN1CYP2C9 | |
| SCHEMBL23452638 | 0.84 | PIN1 (0.52) | KMT2ACDK2PIN1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812564-A | EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof | 厦门宝太生物科技股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-117756805-A | Pteridinone derivatives as RSK inhibitors and their use | 华东师范大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117384160-A | Compounds as CDK inhibitors and uses thereof | 华东理工大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-117384161-A | Compound for targeted degradation of CDK protein and application thereof | 华东理工大学 | 2024-01-12 | — | — | CN | disclosed |
| WO-2024008097-A1 | COMPOUND FOR TARGETED DEGRADATION OF CDK PROTEIN AND USE THEREOF | 华东理工大学 | 2024-01-11 | — | — | WO | disclosed |
| CN-116529251-A | Substituted fused bicyclic compounds as kinase inhibitors and their use | 上海瑛派药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
| WO-2006076595-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060047118-A1 | New pteridinones as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| WO-2006021547-A1 | PTERIDINONES USED AS PLK (POLO LIKE KINASE) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1590341-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004065378-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| CN-1373763-A | Pteridinones and kinase inhibitors | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | CN | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | KMT2A 919/4885CDK2 3/4885PIN1 781/4885 |
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | NUAK1, NUAK2, NEK11 | KMT2A 897/4885CDK2 16/4885PIN1 1401/4885 |
| US-20060047118-A1 | New pteridinones as PLK inhibitors | PLK2, PLK4, PLK3 | KMT2A 1861/4885CDK2 29/4885PIN1 3007/4885 |
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | KMT2A 221/4885CDK2 1157/4885PIN1 899/4885 |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | KMT2A 669/4885CDK2 4/4885PIN1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.